Lexeo Therapeutics reported second quarter 2026 financial results, posting a net loss of $25.9 million or $0.30 per share, compared to a $26.1 million loss in the prior year period. Research and development expenses increased to $19.0 million from $14.7 million, while general and administrative expenses decreased significantly to $9.0 million from $16.0 million. The company ended the quarter with $234.2 million in cash, cash equivalents, and investments, providing an operational runway into 2028. Clinically, Lexeo initiated the SUNRISE-FA 2 pivotal trial for its lead candidate LX2006 in Friedreich ataxia cardiomyopathy, enrolling the first patient in June 2027, with topline data expected in the second half of 2027. Additionally, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy based on interim clinical data. Lexeo Therapeutics is a clinical-stage genetic medicine company developing novel treatments for cardiovascular diseases.

Lexeo Therapeutics, Inc. announced regulatory updates for LX2006, its gene therapy candidate for treating Friedreich ataxia (FA) cardiomyopathy, including a pivotal study design intended to support accelerated approval. The company hosted a conference call and webcast to discuss these updates. Lexeo Therapeutics, Inc. is a biotechnology company focused on developing gene therapies for rare diseases.